These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27488874)

  • 41. Improved survival in BRCA2 carriers with ovarian cancer.
    Pal T; Permuth-Wey J; Kapoor R; Cantor A; Sutphen R
    Fam Cancer; 2007; 6(1):113-9. PubMed ID: 17160431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Significance of Clinical Factors Including
    Kim JY; Park H; Lee DW; Kim MJ; Shin JE; Lee KE; Lee HN
    Anticancer Res; 2022 Oct; 42(10):4945-4954. PubMed ID: 36191979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
    Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases.
    Fu Y; Wang X; Pan Z; Xie X
    Front Med; 2014 Mar; 8(1):91-5. PubMed ID: 24370920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
    Majdak EJ; Debniak J; Milczek T; Cornelisse CJ; Devilee P; Emerich J; Jassem J; De Bock GH
    Cancer; 2005 Sep; 104(5):1004-12. PubMed ID: 16047333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

  • 52. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
    Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis].
    Tao T; Yang JX; Shen K; Cao DY
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):20-25. PubMed ID: 28190311
    [No Abstract]   [Full Text] [Related]  

  • 54. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
    Gallagher DJ; Konner JA; Bell-McGuinn KM; Bhatia J; Sabbatini P; Aghajanian CA; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Ann Oncol; 2011 May; 22(5):1127-1132. PubMed ID: 21084428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.
    Foote JR; Lopez-Acevedo M; Buchanan AH; Secord AA; Lee PS; Fountain C; Myers ER; Cohn DE; Reed SD; Havrilesky LJ
    J Oncol Pract; 2017 Feb; 13(2):e120-e129. PubMed ID: 28045615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
    Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
    Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
    Vos JR; Mourits MJ; Teixeira N; Jansen L; Oosterwijk JC; de Bock GH
    Gynecol Oncol; 2016 Feb; 140(2):289-94. PubMed ID: 26631606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.